|Antibody & Protein Therapeutics Summit|
Antibodies in Oncology & Beyond
Antibody Drug Conjugates
Novel Protein Therapeutics
We invite you to attend the 3rd Antibody Drug Conjugates Conference, which will take place July 11-12, 2017 in Baltimore, MD. This event will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues from different sectors and gain a fresh perspective on the emergence of recent data from ADC clinical trials, new linkers and payloads, personalized healthcare, site specific attachment, and ADC therapeutics.
With the field of antibody drug conjugates rapidly expanding and the increasing number of ADC clinical trials, novel therapeutics are emerging. The ADC therapeutic area combines synthetic chemistry with rationale biology and is advancing monoclonal antibody treatments into the realm of precision medicine with improved effectiveness and therapeutic indices.
- Antibody and Protein Discovery Technologies
- Payloads, Linkers, and Alternative Strategies in ADCs
- Important Considerations During Preclinical Development
- Advances in Antibody Engineering
- Regulatory Considerations of Bringing Antibody Therapies to Market
We hope to see you there!
The 2017 Advisory Committee
|2017 Program Director|
|Victor-Jeffrey Leyton, Université de Sherbrooke|
|2017 Advisory Board Members|
|Neeraj Agrawal, Amgen|
|Ahuva Nissim, Queen Mary University|
|Amandeep Gakhal, Sutro Biopharma|
|Ann White, University of Southampton|
|Bill Harriman , Crystal Bioscience|
|Birgit Schoeberl, Merrimack Pharmaceuticals|
|Elad Firnberg, Revolve Biotechnologies|
|Ernesto Freire, Johns Hopkins University|
|Nicolas Fischer, Novimmune SA|
|Gregory Adams, Eleven Biotherapeutics|
|Janos Luka, Walter Reed Army Institute of Research|
|Matthew Robinson, Immunome, Inc|
|Michael R. Dyson, IONTAS Ltd|
|Andreas Pahl, Heidelberg Pharma|
|Pedro Berraondo López, CIMA, University of Navarra|
|Darren Schofield, MedImmune|
|Seema Kumar, EMD Serono|
|Jamshid Tanha, University of Ottawa|
|Thomas Pillow, Genentech|
|Medha J. Tomlinson, Abbvie|
|Yan Chen, Genentech|
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
Morphotek® is a biotechnology company developing antibody-based therapies. In oncology, we focus on underlying disease pathways and overcoming immunosuppressive effects by tumors on immune-mediated therapies. As part of this approach, our ADC Services employ our REsidue-SPEcific Conjugation Technology™ (RESPECT™) and proprietary payloads to develop ADCs for Morphotek and our clients.
NanoTemper Technologies develops, produces and markets innovative technologies and instrumentation used by thousands of scientists worldwide. The company stands for a strong commitment to quality and high-precision instrumentation made in Germany. The experienced team of experts focuses on users' benefits by ensuring maximum efficiency for research in pharmaceutical and biotechnology industries.
BSI is well known for its PEAKS software suite and service platform for proteomics discovery and therapeutic protein characterization by LC-MS. The benchmark de novo sequencing capabilities offers advanced solutions for proteomic and therapeutic protein discovery as provided through peptide/protein identification & quantification, peptide mapping, PTMs and sequence variants.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.